|
1
|
Reichel A, Hamm H, Wiegering V, Wiewrodt
B, Neubauer H, Ernestus K and Winkler B: Kaposiform
hemangioendothelioma with Kasabach-Merritt syndrome: Successful
treatment with sirolimus. J Dtsch Dermatol Ges. 15:329–331. 2017.
View Article : Google Scholar
|
|
2
|
DeFatta RJ, Verret DJ, Adelson RT, Gomez A
and Myers LL: Kaposiform hemangioendothelioma: Case report and
literature review. Laryngoscope. 115:1789–1792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yasui N, Koh K, Kato M, Park MJ, Tomizawa
D, Oshima K, Uchisaka N, Gocho Y, Arakawa A, Seki M, et al:
Kasabach-Merritt phenomenon: A report of 11 cases from a single
institution. J Pediatr Hematol Oncol. 35:554–558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Croteau SE, Liang MG, Kozakewich HP,
Alomari AI, Fishman SJ, Mulliken JB and Trenor CC III: Kaposiform
hemangioendothelioma: Atypical features and risks of
Kasabach-Merritt phenomenon in 107 referrals. J Pediatr.
162:142–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yadav D, Maheshwari A, Aneja S, Seth A and
Chandra J: Neonatal Kasabach-Merritt phenomenon. Indian J Med
Paediatr Oncol. 32:238–241. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blatt J, Stavas J, Moats-Staats B, Woosley
J and Morrell DS: Treatment of childhood kaposiform
hemangioendothelioma with sirolimus. Pediatr Blood Cancer.
55:1396–1398. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iacobas I, Simon ML, Amir T, Gribbin CE,
McPartland TG, Kaufman MR, Calderwood S and Nosher JL: Decreased
vascularization of retroperitoneal kaposiform hemangioendothelioma
induced by treatment with sirolimus explains relief of symptoms.
Clin Imaging. 39:529–532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jahnel J, Lackner H, Reiterer F,
Urlesberger B and Urban C: Kaposiform hemangioendothelioma with
Kasabach-Merritt phenomenon: From vincristine to sirolimus. Klin
Padiatr. 224:395–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kai L, Wang Z, Yao W, Dong K and Xiao X:
Sirolimus, a promising treatment for refractory Kaposiform
hemangioendothelioma. J Cancer Res Clin Oncol. 140:471–476. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adams DM, Trenor CC III, Hammill AM, Vinks
AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell
LM, Brookbank C, et al: Efficacy and safety of sirolimus in the
treatment of complicated vascular anomalies. Pediatrics.
137:e201532572016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zimmerman JJ and Kahan BD:
Pharmacokinetics of sirolimus in stable renal transplant patients
after multiple oral dose administration. J Clin Pharmacol.
37:405–415. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
MacDonald A, Scarola J, Burke JT and
Zimmerman JJ: Clinical pharmacokinetics and therapeutic drug
monitoring of sirolimus. Clin Ther. 22 (Suppl B):B101–B121. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chevillard L, Sabo N, Tod M, Labat L,
Chasport C, Chevaleyre C, Thibaut F, Barre J, Azuar J, Questel F,
et al: Population pharmacokinetics of oral baclofen at steady-state
in alcoholic-dependent adult patients. Fundam Clin Pharmacol.
32:239–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marsot A, Michel F, Chasseloup E, Paut O,
Guilhaumou R and Blin O: Phenobarbital in intensive care unit
pediatric population: Predictive performances of population
pharmacokinetic model. Fundam Clin Pharmacol. 31:558–566. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang DD, Lu JM, Li Q and Li ZP: Population
pharmacokinetics of tacrolimus in paediatric systemic lupus
erythematosus based on real-world study. J Clin Pharm Ther.
43:476–483. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vadcharavivad S, Praisuwan S,
Techawathanawanna N, Treyaprasert W and Avihingsanon Y: Population
pharmacokinetics of tacrolimus in Thai kidney transplant patients:
Comparison with similar data from other populations. J Clin Pharm
Ther. 41:310–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiao Z, Shi XJ, Li ZD and Zhong MK:
Population pharmacokinetics of sirolimus in de novo Chinese adult
renal transplant patients. Br J Clin Pharmacol. 68:47–60. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jonsson EN and Karlsson MO: Xpose-an
S-PLUS based population pharmacokinetic/pharmacodynamic model
building aid for NONMEM. Comput Methods Programs Biomed. 58:51–64.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fasolo A and Sessa C: Current and future
directions in mammalian target of rapamycin inhibitors development.
Expert Opin Investig Drugs. 20:381–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thomson AH and Whiting B: Bayesian
parameter estimation and population pharmacokinetics. Clin
Pharmacokinet. 22:447–467. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kauffman RE and Kearns GL: Pharmacokinetic
studies in paediatric patients. Clinical and ethical
considerations. Clin Pharmacokinet. 23:10–29. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Emoto C, Fukuda T, Mizuno T, Schniedewind
B, Christians U, Adams DM and Vinks AA: Characterizing the
developmental trajectory of sirolimus clearance in neonates and
infants. CPT Pharmacometrics Syst Pharmacol. 5:411–417. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mizuno T, Fukuda T, Emoto C,
Mobberley-Schuman PS, Hammill AM, Adams DM and Vinks AA:
Developmental pharmacokinetics of sirolimus: Implications for
precision dosing in neonates and infants with complicated vascular
anomalies. Pediatr Blood Cancer. 642017.doi: 10.1002/pbc.26470.
PubMed/NCBI
|
|
24
|
Mizuno T, Emoto C, Fukuda T, Hammill AM,
Adams DM and Vinks AA: Model-based precision dosing of sirolimus in
pediatric patients with vascular anomalies. Eur J Pharm Sci 109S.
S124–S131. 2017. View Article : Google Scholar
|
|
25
|
Lampen A, Zhang Y, Hackbarth I, Benet LZ,
Sewing KF and Christians U: Metabolism and transport of the
macrolide immunosuppressant sirolimus in the small intestine. J
Pharmacol Exp Ther. 285:1104–1112. 1998.PubMed/NCBI
|
|
26
|
Sattler M, Guengerich FP, Yun CH,
Christians U and Sewing KF: Cytochrome P-450 3A enzymes are
responsible for biotransformation of FK506 and rapamycin in man and
rat. Drug Metab Dispos. 20:753–761. 1992.PubMed/NCBI
|
|
27
|
Yang JW, Liao SS, Zhu LQ, Zhao Y, Zhang Y,
Sun XY, Rao W, Qu W, Li WZ and Sun LY: Population pharmacokinetic
analysis of tacrolimus early after Chinese pediatric liver
transplantation. Int J Clin Pharmacol Ther. 53:75–83. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Anderson BJ and Holford NH:
Mechanism-based concepts of size and maturity in pharmacokinetics.
Annu Rev Pharmacol Toxicol. 48:303–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang DD, Chen X and Li ZP: Wuzhi capsule
and haemoglobin influence tacrolimus elimination in paediatric
kidney transplantation patients in a population pharmacokinetics
analysis: A retrospective study. J Clin Pharm Ther. Mar
12–2019.doi: 10.1111/jcpt.12828 (Epub ahead of print). View Article : Google Scholar
|
|
30
|
Wang D, Chen X, Xu H and Li Z: Population
pharmacokinetics and dosing regimen optimisation of tacrolimus in
Chinese pediatric hematopoietic stem cell transplantation patients.
Xenobiotica. 1–8. 2019.(Epub ahead of print). View Article : Google Scholar
|
|
31
|
Wang D, Chen X and Li Z: Cyclosporin
population pharmacokinetics in pediatric refractory nephrotic
syndrome based on real-world studies: Effects of body weight and
spirolactone administration. Exp Ther Med. 17:3015–3020.
2019.PubMed/NCBI
|
|
32
|
Zimmerman JJ: Exposure-response
relationships and drug interactions of sirolimus. AAPS J.
6:e282004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dansirikul C, Morris RG, Tett SE and
Duffull SB: A Bayesian approach for population pharmacokinetic
modelling of sirolimus. Br J Clin Pharmacol. 62:420–434. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tejani A, Alexander S, Ettenger R, Lerner
G, Zimmerman J, Kohaut E and Briscoe DM: Safety and
pharmacokinetics of ascending single doses of sirolimus (Rapamune,
rapamycin) in pediatric patients with stable chronic renal failure
undergoing dialysis. Pediatr Transplant. 8:151–160. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Emoto C, Fukuda T, Venkatasubramanian R
and Vinks AA: The impact of CYP3A5*3 polymorphism on sirolimus
pharmacokinetics: Insights from predictions with a
physiologically-based pharmacokinetic model. Br J Clin Pharmacol.
80:1438–1446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang M, Duan BL, Yuan YJ, Su X, Zheng H,
Wang FS and Sun H: Population pharmacokinetic characteristics of
sirolimus in healthy Chinese subjects and renal transplant
patients. Int J Clin Pharmacol Ther. 54:433–441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mizuno T, Fukuda T, Christians U,
Perentesis JP, Fouladi M and Vinks AA: Population pharmacokinetics
of temsirolimus and sirolimus in children with recurrent solid
tumours: A report from the Children's Oncology Group. Br J Clin
Pharmacol. 83:1097–1107. 2017. View Article : Google Scholar : PubMed/NCBI
|
